# Raydiant Oximetry

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/raydiant-oximetry

- Industry: Medical Devices & Equipment
- Headquarters: San Ramon, US
- Website: www.raydiantoximetry.com
- Total disclosed funding: $18M
- Latest round: Series A (May 28, 2024)
- Investors on record: 15

## About

Raydiant Oximetry, Inc., based in the US, focuses on enhancing fetal health monitoring with its innovative noninvasive sensor technology designed to measure fetal oxygen levels during childbirth.Founded in 2015, Raydiant Oximetry, Inc. operates out of San Ramon, US, and specializes in fetal health monitoring. The company's latest funding round, a Series A amounting to USD 7.5 mn, was led by Cross-Border Impact Ventures. Neil Ray serves as both the founder and CEO, guiding the company through its current developments. The firm has successfully completed 13 deals to date, with its most recent deal occurring on May 28, 2024. The total amount raised by Raydiant Oximetry stands at USD 7.5 mn, with a current valuation of USD 25.368 mn.Raydiant Oximetry specializes in advancing fetal health monitoring through its core product, Lumerah™, a noninvasive sensor technology designed to directly measure fetal oxygen levels during childbirth. This innovative fetal pulse oximeter aims to significantly reduce the mortality and morbidity rates among mothers and infants, addressing critical issues related to current electronic fetal monitoring practices. The technology has been shown to improve the sensitivity and specificity in detecting fetal distress, which is vital for obstetrical providers who require reliable tools for evaluating fetal oxygenation. Lumerah™ is currently in the preclinical trial phase and has received 'Breakthrough Device' status from the FDA to expedite its market approval. The primary target markets for Raydiant Oximetry include hospitals and healthcare facilities across the United States, with a focus on enhancing maternal and neonatal care during labor and delivery.Raydiant Oximetry's revenue model is structured around B2B transactions with healthcare providers, including hospitals and obstetrical clinics that require advanced fetal monitoring solutions. The company has successfully closed funding rounds, including a USD 5.6 mn Series A round led by VCapital, indicating strong investor confidence in its product offerings. The business transactions typically involve direct sales agreements or partnerships with healthcare entities, allowing these providers to integrate Lumerah™ into their existing labor and delivery protocols. The organization has also secured grants from multiple sources, such as the Bill & Melinda Gates Foundation and the government of Ireland, which further supports its developmental efforts. Future revenue streams are anticipated to emerge from the adoption of Lumerah™ in clinical settings as it receives market approval and demonstrates improved outcomes in maternal and infant health.In May 2024, Raydiant Oximetry, Inc. raised USD 7.5 mn in Series A funding, led by Cross-Border Impact Ventures, RH Capital, Global Health Impact Fund, VCapital, and the March of Dimes Innovation Fund. The company will utilize this funding to support two clinical trials, including the Daisy™ and Lumerah™ technologies. The strategy includes accelerating the deployment of Lumerah™ in clinical settings as it moves closer to market approval, with expectations to enhance maternal and neonatal care significantly.

## Funding rounds

- Series A, May 28, 2024, $7.5M — March of Dimes Foundation, V-Capital, Global Health Impact Funds, Rhia Ventures, Cross-Border Impact Ventures
- Series A, Nov 1, 2021, $5M — Band of Angels, V-Capital, KOFA Healthcare Investments, Rhia Ventures, Avestria Ventures, SteelSky Ventures, FemHealth Ventures
- Seed, Mar 5, 2020, $0.1M — SpringTide Capital Management
- Series A, Oct 28, 2019, $5.6M — Band of Angels, Mass Medical Angels, AngelMD, VCapital, Rhia Ventures, Avestria Ventures, MD Angels

## Investors

- Band of Angels (https://capitalatlas.ai/funds/band-of-angels) — Series A
- Mass Medical Angels — Series A
- AngelMD — Series A
- VCapital (https://capitalatlas.ai/funds/vcapital) — Series A
- Rhia Ventures (https://capitalatlas.ai/funds/rhia-ventures) — Series A
- Avestria Ventures (https://capitalatlas.ai/funds/avestria-ventures) — Series A
- MD Angels (https://capitalatlas.ai/funds/md-angels) — Series A
- SpringTide Capital Management (https://capitalatlas.ai/funds/springtide-capital-management) — Seed
- V-Capital (https://capitalatlas.ai/funds/v-capital) — Series A
- KOFA Healthcare Investments (https://capitalatlas.ai/funds/kofa-healthcare-investments) — Series A
- SteelSky Ventures (https://capitalatlas.ai/funds/steelsky-ventures) — Series A
- FemHealth Ventures (https://capitalatlas.ai/funds/femhealth-ventures) — Series A
- March of Dimes Foundation — Series A
- Global Health Impact Funds (https://capitalatlas.ai/funds/global-health-impact-funds) — Series A
- Cross-Border Impact Ventures (https://capitalatlas.ai/funds/cross-border-impact-ventures) — Series A